日前，Saol Therapeutics宣布，美国FDA已受理其在研疗法SL1009的新药申请（NDA），用于治疗丙酮酸脱氢酶复合物缺乏症（PDCD）。FDA已授予该申请优先审评资格，并设定PDUFA日期为2025年5月27日。

Researchers have developed a new method for growing T cells in the lab, allowing them to survive longer and fight cancer more effectively. This advancement, detailed in Cell Metabolism, could ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.